Elevated Erythritol: A Marker of Metabolic Dysregulation or Contributor to the Pathogenesis of Cardiometabolic Disease?
Elevated Erythritol: A Marker of Metabolic Dysregulation or Contributor to the Pathogenesis of Cardiometabolic Disease?
复制标题
DOI：
10.3390/nu15184011
复制
发表时间：
2023-09-16
期刊：
影响因子：
5.9
通讯作者：
Stanhope KL
中科院分区：
文献类型：
--
作者：
Mazi TA;Stanhope KL
赤藓糖醇是一种非营养性糖替代品，可由人类内源产生。维特科夫斯基等人。报道称，在三个独立队列中，循环赤藓糖醇升高与不良心血管事件相关，在体外和离体证明赤藓糖醇促进血小板活化，并在注射赤藓糖醇的小鼠中显示出更快的凝血时间。结论是赤藓糖醇会促进血栓形成。这篇叙述性评论提供了评估这些数据和结论时需要考虑的额外证据。我们对所有与赤藓糖醇暴露相关的研究进行了检索，重点关注那些报告血管健康结果的研究。由于先天性代谢缺陷而导致赤藓糖醇水平长期升高的患者不会表现出较高的血小板活化或血栓形成风险。大多数动物摄入高水平赤藓糖醇的长期研究并不支持其在血小板活化和血栓形成中的作用。关于长期摄入赤藓糖醇的影响的临床数据有限。赤藓糖醇可能只是血糖受损引起的磷酸戊糖途径失调的标志。然而，这一建议和 Witkowski 等人的研究结果。需要进一步检查。需要进行临床试验来检查赤藓糖醇消耗对心脏代谢结果的长期影响，以测试膳食赤藓糖醇与心脏代谢风险之间的因果关系。在获得这些试验的支持性数据之前，不能得出饮食赤藓糖醇促进血小板活化、血栓形成和心脏代谢风险的结论。
Erythritol is a non-nutritive sugar replacement that can be endogenously produced by humans. Witkowski et al. reported that elevated circulating erythritol is associated with adverse cardiovascular events in three independent cohorts, demonstrated in vitro and ex vivo that erythritol promotes platelet activation, and showed faster clotting time in mice injected with erythritol. It was concluded that erythritol fosters enhanced thrombosis. This narrative review presents additional evidence that needs to be considered when evaluating these data and conclusions. We conducted a search of all studies related to erythritol exposure with focus on those that reported vascular health outcomes. Patients with chronically elevated erythritol levels due to inborn errors of metabolism do not exhibit higher platelet activation or thrombosis risk. Most long-term studies in which animals consumed high levels of erythritol do not support its role in platelet activation and thrombosis formation. Clinical data on the effects of chronic intake of erythritol are limited. Erythritol may be merely a marker of dysregulation in the Pentose Phosphate Pathway caused by impaired glycemia. However, this suggestion and the findings of Witkowski et al. need to be further examined. Clinical trials examining the long-term effects of erythritol consumption on cardiometabolic outcomes are required to test the causality between dietary erythritol and cardiometabolic risk. Until supportive data from these trials are available, it cannot be concluded that dietary erythritol promotes platelet activation, thrombosis, and cardiometabolic risk.
登录
查看更多内容
影响因子：
5.9
作者：
Mazi TA;Stanhope KL
通讯作者：
Stanhope KL
影响因子：
3.7
作者：
Boesten DM;Berger A;de Cock P;Dong H;Hammock BD;den Hartog GJ;Bast A
通讯作者：
Bast A
DOI：
10.7759/cureus.35150
发表时间：
2023-02
期刊：
Cureus
影响因子：
--
作者：
Fallata E;Alamri AM;Alrabee HA;Alghamdi AA;Alsaearei A
通讯作者：
Alsaearei A
DOI：
10.1007/8904_2015_474
发表时间：
2016-01-01
期刊：
JIMD REPORTS, VOL 26
影响因子：
--
作者：
Banne, Ehud;Meiner, Vardiella;Eventov-Friedman, Smadar
通讯作者：
Eventov-Friedman, Smadar
影响因子：
4.1
作者：
Ahmadizar F;Wang K;Aribas E;Fani L;Heshmatollah A;Ikram MK;Kavousi M
通讯作者：
Kavousi M